An overview of some of the vaccines currently licensed for vaccination of domesticated animals and wildlife by mucosal routes is provided in Table 1. with comparable characteristics in other species. Successful development of vaccines to prevent and treat ascending infections of the reproductive tract of cattle set a precedent for applications in other species including humans. Studies of mucosal adjuvants and delivery systems continue at the interface between passive and active immunity, with the goal of inducing the earliest possible protection against enteric and respiratory pathogens of neonates. Keywords: Abortion, Adjuvant, Enteritis, Contamination, Intranasal, Mucosal, Oral, Pneumonia, Vaccine, Veterinary Introduction Despite improvements in nutrition, genetics, housing, and therapeutics, diseases of the respiratory, reproductive, and gastrointestinal tracts of domestic animals and poultry continue to be major causes of morbidity and mortality. Although vaccines have been developed and licensed for prevention of many of these diseases, there is a Rabbit Polyclonal to ACRO (H chain, Cleaved-Ile43) need for improvement in vaccine efficacy and for new vaccines. Reasons for low vaccine efficacy include inappropriate, unstable, or outdated antigens in vaccine preparations (e.g., in?vitro expressed antigens instead of in?vivo expressed antigens), inappropriate immune responses (e.g., systemic instead of mucosal, or Th2 type instead of Th1 type or vise versa), and improper use of normally efficacious vaccines (e.g., improper timing of vaccination) (Tizard, 2013). An overview of some of the vaccines currently licensed for vaccination of domesticated animals and wildlife by mucosal routes is usually provided in Table 1 . Many of these vaccines consist of pathogens attenuated by traditional methods, but designed virus-vectored vaccines are now used extensively (by both mucosal and parenteral routes) in veterinary medicine. Table 1 Examples of Commercial Veterinary Vaccines Administered by Mucosal Routesa subsp. species administered in ovo, or to chicks at 1?day of age in a spray cabinet or sprayed on feed C goal is controlled exposureInfectious bursal disease (IBD) virusIBDAttenuated computer virus or herpesvirus of turkeys (HVT)-vectored vaccineIBD in drinking water or HVT-vectored vaccine in ovo Open GSK2330672 in a separate window aFor a more extensive summary of veterinary vaccines that includes vaccines given by parenteral routes, see the previous (3rd) edition of this GSK2330672 book. bAgents and vaccines have been selected as representative of common disease issues and current commercial vaccines. Vaccine data have been collated from manufacturers product monographs unless indicated normally. cAvailable at: http://www.aphis.usda.gov/wildlife_damage/oral_rabies/downloads/NationalReport_2010.pdf (accessed 13.03.14). dNandi et?al. (2009). eWilliams and Zedek (2010). The majority of current poultry vaccines are attenuated brokers delivered in ovo, orally, intranasally (IN) or by other mucosal routes, for reasons of ease of administration, economy, and protective efficacy. In comparison, fewer vaccines for domestic mammals are delivered by mucosal routes. Management practices for mammals differ from those for poultry; mass vaccination techniques for mucosal delivery have been developed for poultry, but have not been pursued as zealously for mammals. Recently however, a number of attenuated live vaccines for IN administration have been developed for respiratory tract infections, using traditional methodologies. Improved protective efficacy and rapid onset of immunity compared to killed vaccine products have led to common acceptance. Attenuated live oral vaccines for enteric diseases have also been marketed, but in many cases efficacy has been disappointing due to lack of potency in adults or interference by maternal antibodies in suckling animals. Better strategies for induction of immunity in the gastrointestinal tract are needed, especially for neonates in the presence of maternal antibodies. In contrast, effective parenteral vaccines for the most common diseases of the reproductive tract in veterinary species have been available for years, and there has been little motivation to develop mucosal vaccines. Many of the diseases of the respiratory and gastrointestinal tracts are most devastating in the neonatal period. For these GSK2330672 diseases active immunization may not provide protection before natural exposure to the pathogen. Maternal vaccination to enhance passive immunity has been widely used in veterinary medicine, especially for control of enteric diseases. Practical difficulties arise, however, with diseases such as parvovirus enteritis in pups in which a easy transition must be made from protection by passive maternal antibodies to protection by active immunity, without permitting a windows in.